v2.4.0.6
Business combinations (Details Textual) (USD $)
In Millions, unless otherwise specified
0 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended
Dec. 10, 2012
de CODE Genetics [Member]
Jul. 05, 2012
Kai Pharmaceuticals [Member]
Jun. 12, 2012
Mustafa Nevzat Pharmaceuticals [Member]
Dec. 31, 2012
Micromet Inc [Member]
Mar. 07, 2012
Micromet Inc [Member]
Mar. 07, 2012
Micromet Inc [Member]
Developed Technology [Member]
Dec. 31, 2012
Biovex Group Inc [Member]
Mar. 04, 2011
Biovex Group Inc [Member]
Dec. 31, 2011
Other Acquisitions [Member]
Dec. 31, 2011
Laboratorio Quimco Farmaceutico Bergamo Ltda [Member]
Business Acquisition [Line Items]                    
Total consideration $ 401 $ 332 $ 677   $ 1,146     $ 407    
Finite-lived intangible assets comprised of databases and other proprietary information 401                  
Finite-lived intangible assets, estimated useful life (in years) 10 years   8 years     10 years        
Deferred tax liabilities 80                  
Other assets and liabilities, net 13                  
Goodwill arising from business combinations 93 125 380   330     170 265  
Impairment charge resulting from termination of a non-key program under an outlicensing arrangement       19            
Contingent consideration obligations             575 575    
Estimated aggregate fair value of the contingent consideration obligations               190    
Aggregate acquisition date consideration for business combinations               597 453  
Tax deductible portion of goodwill arising from a business combination                   130
Property plant equipment acquired in business combinations     100           99  
Amortizable intangible assets acquired in business combinations     163     350     58  
Other assets (liabilities), net   $ 26 $ (52)   $ (24)     $ (2) $ 31